Published 2 years ago

Cancer research: Tübingen biotech company Immatics agrees billion-dollar deal with Bristol-Myers

Summary by Handelsblatt

The US company Bristol-Myers Squibb is expanding its alliance with Immatics — and wants to invest in the development of new cell therapies to fight tumors and blood cancer.

0 Articles

All

Left

Center

Right

Handelsblatt

Cancer research: Tübingen biotech company Immatics agrees billion-dollar deal with Bristol-Myers

The US company Bristol-Myers Squibb is expanding its alliance with Immatics — and wants to invest in the development of new cell therapies to fight tumors and blood cancer.

2 years ago·Düsseldorf, Germany

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated2 years agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Cancer research: Tübingen biotech company Immatics agrees billion-dollar deal with Bristol-Myers

0 Articles

0 Articles

Cancer research: Tübingen biotech company Immatics agrees billion-dollar deal with Bristol-Myers

Cancer research: Tübingen biotech company Immatics agrees billion-dollar deal with Bristol-Myers

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics